Validation of an Artificial Intelligence System Based on Raman Spectroscopy for Diagnosis of Gastric Premalignant Lesions and Early Gastric Cancer
NCT04869618 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2021-05-03
Summary
Early detection and treatment of gastric premalignant lesion and early gastric cancer (EGC) have been proposed to improve outcomes of gastric cancer. Gastric dysplasia is a premalignant lesion and the penultimate stage in gastric carcinogenesis. On white light endoscopy (WLE), it is difficult to distinguish gastric dysplasia and EGC from benign pathology such as gastric intestinal metaplasia (GIM). Image enhanced endoscopy such as narrow-band imaging (NBI) is recommended to improve characterization of suspicious gastric lesions detected on WLE. Magnified-endoscopy with NBI (ME-NBI) have been shown to be superior to HD-WLE for diagnosis of GIM and EGC. Data on gastric dysplasia is less robust. Ultimately, biopsy is required to confirm diagnosis of gastric dysplasia/EGC. Gastric dysplasia can be classified into low-grade dysplasia (LGD) or high-grade dysplasia (HGD). Biopsy sampling may not be representative of the final histopathological grade of resected specimens and may under-stage dysplasia. Thus, endoscopic resection (ER) is recommended for gastric dysplasia and EGC on biopsy for diagnostic and therapeutic purpose. The current gap is to improve concordance of endoscopic and histologic findings of gastric dysplasia and early gastric cancer. Raman spectroscopy based artificial intelligence system (SPECTRA IMDx) was developed to provide an objective method to identify patients with gastric premalignant lesions and EGC. SPECTRA IMDx interrogate tissues at the cellular level and utilizes molecular information to provide actionable information to endoscopist during gastroscopy. Studies on diagnostic performance using Raman spectroscopy analysis devices have shown high sensitivity and specificity in detection of gastric cancer and precancerous lesions compared to WLE. However, these studies included few GIM, gastric dysplasia and gastric carcinoma. It is still unclear if Raman spectroscopy outperforms WLE in diagnosis of gastric HGD and EGC. In addition, the Raman spectroscopy algorithm is only able to characterize lesions into high risk (HGD/EGC) versus low risk (GIM/LGD/Gastritis/Normal). It is also uncertain if this technology is able to differentiate GIM and LGD. We plan to conduct a prospective trial to validate the diagnostic accuracy of SPECTRA for prediction of gastric HGD and EGC prior to gastric ER. Hypothesis: SPECTRA IMDx is able to differentiate higher risk lesions (HGD/EGC) from lower risk tissue/lesion (GIM/LGD/Gastritis/Normal)
Conditions
- Gastric Dysplasia
- Gastric Intestinal Metaplasia
- Gastric Cancer
Interventions
- DEVICE
-
Raman spectroscopy based device (SPECTRA IMDx)
The SPECTRA IMDx system is developed on the basis of Raman spectroscopy. It comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx system also comprises a SPECTRA IMDx probe that can be connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal, which is then parsed through an analysis algorithm for diagnosis.
Sponsors & Collaborators
-
Changi General Hospital
lead OTHER
Principal Investigators
-
Chin Kimg Tan, MD · Changi General Hospital
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 21 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-31
- Primary Completion
- 2022-03-31
- Completion
- 2023-03-31
Countries
- Singapore
Study Locations
More Related Trials
-
Application of Artificial Intelligence for Early Diagnosis of Gastric Cancer During Optical Enhancement Magnifying Endoscopy
NCT04563416 ·Status: UNKNOWN
-
Artificial Intelligence-assisted Confocal Laser Endomicroscopy Identification of Intestinal Metaplasia Severity
NCT05462743 ·Status: UNKNOWN
-
Magnifying Endoscopy With Narrow Band Imaging Versus Endoscopic Ultrasonography for Prediction of Tumor Invasion Depth in Early Gastric Cancer: A Prospective Comparative Study
NCT03546257 ·Status: UNKNOWN
-
Artificial Intelligence Confocal Laser Endomicroscopy for Real-time Assessment of Gastric Cancer Risk.
NCT05459428 ·Status: UNKNOWN
-
Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy
NCT01398579 ·Status: UNKNOWN ·Phase: PHASE1
-
Application of Indocyanine Green Labeled Fluorescent Laparoscopy in Proximal Gastric Cancer
NCT05369117 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Optical Imaging of Gastrointestinal Biopsy Samples and Their Correlation With Histology
NCT04565704 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
NCT03468634 ·Status: COMPLETED ·Phase: NA
-
Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer
NCT04593615 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
NCT05618821 ·Status: RECRUITING ·Phase: PHASE2
-
Application of Linked Color Imaging(LCI) in Diagnosis of Early Gastric Cancer(EGC)
NCT03661671 ·Status: UNKNOWN ·Phase: NA
-
Usefulness of Near-focus With Narrow-band Imaging
NCT02661945 ·Status: COMPLETED ·Phase: NA
-
OLGA Stage is More Appropriate in Predicting Early Gastric Cancer
NCT02562976 ·Status: COMPLETED
-
Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma
NCT01642797 ·Status: UNKNOWN ·Phase: NA
-
Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo Measurements
NCT05247346 ·Status: UNKNOWN ·Phase: NA
-
Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
NCT06822413 ·Status: RECRUITING
-
Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
NCT07276854 ·Status: NOT_YET_RECRUITING
-
Web-Mediated Risk Assessment for Endoscopic Screening of Gastric Cancer
NCT03484949 ·Status: UNKNOWN ·Phase: NA
-
Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer
NCT04973475 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Automatic Evaluation of the Extent of Intestinal Metaplasia With Artificial Intelligence
NCT05459610 ·Status: UNKNOWN
-
Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis
NCT04840056 ·Status: RECRUITING
-
3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
NCT06161207 ·Status: RECRUITING ·Phase: PHASE3
-
A Pilot Study on Usefulness of Probe-based Confocal Laser Endomicroscopy Targeted Gastric Biopsy
NCT02089373 ·Status: COMPLETED ·Phase: NA
-
The Diagnostic Ability of White Light Endoscopy and Magnifying Endoscopy With Optical Enhancement System
NCT04411589 ·Status: UNKNOWN ·Phase: NA
-
Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection
NCT02189226 ·Status: COMPLETED ·Phase: NA